BRPI0413749A - uso de amoxapina ou de um sal farmaceuticamente aceitável, composição farmacêutica, e, kit - Google Patents

uso de amoxapina ou de um sal farmaceuticamente aceitável, composição farmacêutica, e, kit

Info

Publication number
BRPI0413749A
BRPI0413749A BRPI0413749-3A BRPI0413749A BRPI0413749A BR PI0413749 A BRPI0413749 A BR PI0413749A BR PI0413749 A BRPI0413749 A BR PI0413749A BR PI0413749 A BRPI0413749 A BR PI0413749A
Authority
BR
Brazil
Prior art keywords
amoxapine
kit
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
Prior art date
Application number
BRPI0413749-3A
Other languages
English (en)
Inventor
Thomas Ivo Franciscus Cremers
Sandra Hogg Willigers
Jorn Arnt
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BRPI0413749A publication Critical patent/BRPI0413749A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DE AMOXAPINA OU DE UM SEU SAL FARMACEUTICAMENTE ACEITáVEL, COMPOSIçãO FARMACêUTICA, E, KIT". A presente invenção refere-se ao uso de uma combinação de Amoxapina e de um inibidor da recaptação de serotonina (SRI) ou de qualquer outro composto, que causa uma elevação no nível de serotonina extracelular, para o tratamento de depressão e de outros distúrbios afetivos.
BRPI0413749-3A 2003-09-04 2004-09-01 uso de amoxapina ou de um sal farmaceuticamente aceitável, composição farmacêutica, e, kit BRPI0413749A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50079203P 2003-09-04 2003-09-04
DKPA200301269 2003-09-04
PCT/DK2004/000580 WO2005023266A1 (en) 2003-09-04 2004-09-01 The combination of a serotonin reuptake inhibitor and amoxapine

Publications (1)

Publication Number Publication Date
BRPI0413749A true BRPI0413749A (pt) 2006-10-24

Family

ID=34276704

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413749-3A BRPI0413749A (pt) 2003-09-04 2004-09-01 uso de amoxapina ou de um sal farmaceuticamente aceitável, composição farmacêutica, e, kit

Country Status (9)

Country Link
US (1) US20080167290A1 (pt)
EP (1) EP1670479A1 (pt)
JP (1) JP2007504180A (pt)
AU (1) AU2004269857A1 (pt)
BR (1) BRPI0413749A (pt)
IL (1) IL174069A0 (pt)
MX (1) MXPA06002279A (pt)
NO (1) NO20061427L (pt)
WO (1) WO2005023266A1 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
AU2003294470B2 (en) * 2002-11-26 2009-09-17 Alexza Pharmaceuticals, Inc. Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain

Also Published As

Publication number Publication date
JP2007504180A (ja) 2007-03-01
IL174069A0 (en) 2006-08-01
WO2005023266A1 (en) 2005-03-17
MXPA06002279A (es) 2006-05-17
US20080167290A1 (en) 2008-07-10
AU2004269857A1 (en) 2005-03-17
EP1670479A1 (en) 2006-06-21
NO20061427L (no) 2006-03-29

Similar Documents

Publication Publication Date Title
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
CY1118179T1 (el) Φαρμακευτικη συνθεση
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
BRPI0410503B8 (pt) composição tópica e uso da composição
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
ECSP034450A (es) Nueva composicion farmaceutica
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
BRPI0212298B8 (pt) composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
MEP6208A (en) The combination of a serotonin reuptake inhibitor and a 5-ht¿2c? antagonist, inverse agonist or partial agonist
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
BRPI0411665A (pt) uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
BRPI0415713A (pt) mio-inositol hexafosfato para uso tópico
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
MXPA05013016A (es) Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos.
BRPI0519919A2 (pt) composições farmacêuticas compreendendo inibidores da nep, inibidores do sistema de produção de endotelina endógena e inibidores da hmg coa redutase
PA8531701A1 (es) Derivados de pirimidina
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
BR0315346A (pt) Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente, formulação farmacêutica e utilização de inibidor de re-apreensão de norepinefrina em combinação com antagonista de 5-h2a
BRPI0416157A (pt) composição farmacêutica contendo um agonista de adrenoceptor beta-3 e um antagonista alfa e/ou um inibidor de 5-alfa redutase
BR0317771A (pt) Composição farmacêutica, uso da mesma, e, método de tratar distúrbios em um paciente
BRPI0414343A (pt) combinações que compreendem ligantes de alfa-2-delta e inibidores da reabsorção de serotonina/noradrenalina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]